Pharma Business - June 29, 2020
Nordic Nanovector’s Betalutin receives fast-track designation
Nordic Nanovector has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for investigating Betalutin for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least two prior systemic therapies. Nordic Nanovector is evaluating the opportunity to develop Betalutin as a single-agent […]
Drug Development Pharma - May 19, 2020
Betalutin receives positive EMA opinion
Nordic Nanovector has announced that Betalutin (177Lu lilotomab satetraxetan) has received a positive opinion from the European Medicines Agency (EMA) on the application for orphan drug designation for the treatment of marginal zone lymphoma (MZL). The positive opinion is expected to be adopted by the European Commission shortly states the company. “We are very pleased […]
Intellectual Property - May 5, 2020
Nordic Nanovector patent granted
Nordic Nanovector has announced the grant of a US patent covering the use of Betalutin (177Lu-satetraxetan-lilotomab) for sensitising CD37-positive B-cell cancer cells before treatment with CD20 immunotherapy (such as rituximab/RTX). The patent strengthens Nordic Nanovector’s overall patent estate around the use of Betalutin in combination with other drugs that target antigens presented on the surface […]
In a new job - March 25, 2020
Nordic Nanovector appoints new CMO
Nordic Nanovector appoints Dominic Smethurst as Interim Chief Medical Officer with immediate effect. Smethurst replaces Lisa Rojkjaer, who after a handover period will leave Nordic Nanovector to pursue other career opportunities. “I am pleased that we have been able to appoint Dominic as our new Interim CMO. He is a very experienced and commercially focused […]
Financing - December 19, 2019
Nordic Nanovector awarded NOK 12 million in funding from the Norwegian Research Council
Nordic Nanovector’s research and development project Nanoyield has received a non-dilutive funding of NOK 12 million (USD 1.3 million) from the Norwegian Research Council (Forskningsrådet). The Nanoyield project is aimed at optimising the production yield of Nordic Nanovector’s CD37-targeting antibody NNV003. The NNV003 antibody is the antibody component of the radioimmunoconjugate Alpha37. The project will […]
Clinical Trials - August 10, 2019
Nordic Nanovector completes patient enrollment of Phase I trial
The company announces that the final patient has been enrolled in the LYMRIT 37-05 clinical trial of Betalutin (177Lu-satetraxetan-lilotomab) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not eligible for stem cell transplantation. “We are delighted to have reached this important milestone and look forward to the preliminary results during the second half of […]
